Trial Profile
Evaluation of the anti-anginal efficacy and safety of ivabradine used in combination with an anti-anginal monotherapy in patients with stable effort angina pectoris. A 6-week, randomised, double-blind controlled, parallel-group, international, multicentre study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Apr 2016
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary) ; Ischaemic heart disorder therapies
- Indications Angina pectoris
- Focus Therapeutic Use
- Sponsors Servier
- 21 May 2012 Actual end date 31 May 2010 added as reported by Chinese Clinical Trial Register.
- 18 Jan 2012 New trial record